Evidence map›Paper›PMID 39810604›Full record

ArticleDiabetes, obesity & metabolism2025

Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease.

Yasuhiro Matsubayashi, Kazuya Fujihara, Laymon Khin, Efrem d'Àvila Ferreira, Shizuka Takabayashi, Yuko Yamashita, Takaho Yamada, Satoru Kodama, Hirohito Sone

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Within-Person Seasonal Variability of Aminotransferases and Long-Term Glycemic Control in Adults With Type 2 Diabetes (JDDM 85).Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yasuhiro MatsubayashiDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.ORCID 0000-0002-2143-1921
Kazuya FujiharaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.ORCID 0000-0001-6725-4169
Laymon KhinDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.ORCID 0009-0005-9185-7812
Efrem d'Àvila FerreiraDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Shizuka TakabayashiDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Yuko YamashitaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Takaho YamadaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Satoru KodamaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.ORCID 0000-0002-9521-7274
Hirohito SoneDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.

Funding

Japan Society for the Promotion of Science JP23K16814
6 · The paper itself

Abstract

BACKGROUND &

aimsThis study assessed the association of remission of type 2 diabetes mellitus (DM) or metabolic dysfunction-associated steatotic liver disease (MASLD)/related SLD (r-SLD; MASLD with excessive alcohol intake) as defined by the fatty liver index with the risk of cardiovascular disease (CVD).

methodsHealth examination data at baseline and after 2 years (2-Years) were extracted from a nationwide claims database in Japan. Among participants aged 18-72 years with at least 3 years of follow-up, 9345 participants with DM-associated MASLD/r-SLD and 71 932 participants with non-DM MASLD/r-SLD at baseline were included in the study. The participants were stratified by the achievement of remission of MASLD/r-SLD or DM at 2-Years. In each group after stratification, the risk of new-onset CVD during the observation period was analysed using multivariate Cox proportional hazards models.

resultsDuring a median follow-up of 4.9 years (starting from 2-Years), 1368 cases of CVD were observed. The hazard ratio (95% confidence interval) for CVD was 0.50 (0.31-0.80) for participants with remission of DM, 0.65 (0.47-0.91) for participants with remission of MASLD/r-SLD, and 0.34 (0.15-0.77) for participants with remission of both DM and MASLD/r-SLD. Conversely, remission of MASLD/r-SLD was not linked to a reduced risk of CVD in participants with non-DM MASLD/r-SLD.

conclusionThe association of MASLD/r-SLD remission with CVD risk differs greatly in the presence and absence of DM. In patients with DM-MASLD/r-SLD, MASLD/r-SLD remission can significantly reduce CVD risk similarly as remission of DM.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseAdolescentAdultAgedFemaleFollow-Up StudiesHeart Disease Risk FactorsHumansJapanMaleMiddle AgedProportional Hazards ModelsRisk FactorsYoung Adultcardiovascular diseasemetabolic dysfunction‐associated steatotic liver diseaseSteatotic liver diseasetype 2 diabetes

Identifiers

PMID39810604
PMCPMC11885070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.